CVRx
Yahoo Finance • 2 months ago
CVRx outlines $55M-$57M revenue target for 2025 as sales force transition nears completion
Earnings Call Insights: CVRx (CVRX) Q2 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, announced "total revenue of $13.6 million in the second quarter, a 15% increase over the same quarter last year." U.S. Heart Failure revenue... Full story
Yahoo Finance • 2 months ago
CVRx GAAP EPS of -$0.57 misses by $0.05, revenue of $13.6M beats by $0.38M
* CVRx press release [https://seekingalpha.com/pr/20188110-cvrx-reports-second-quarter-2025-financial-and-operating-results] (NASDAQ:CVRX [https://seekingalpha.com/symbol/CVRX]): Q2 GAAP EPS of -$0.57 misses by $0.05. * Revenue of $13.... Full story
Yahoo Finance • 2 months ago
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 months ago
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 months ago
CVRx shares rise on CMS inclusion for Barostim implant procedure
[doctor working in hospital laboratory] sinology/Moment via Getty Images * CVRx (NASDAQ:CVRX [https://seekingalpha.com/symbol/CVRX]) saw a 17% increase in its shares following the announcement that Centers for Medicare and Medicaid Serv... Full story
Yahoo Finance • 2 months ago
Medicare proposes to maintain payment for CVRx's Barostim procedure
MINNEAPOLIS - The Centers for Medicare and Medicaid Services (CMS) has proposed to keep CVRx’s Barostim implant procedure in the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,0... Full story
Yahoo Finance • 2 months ago
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim imp... Full story
Yahoo Finance • 4 months ago
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with c... Full story
Yahoo Finance • 6 months ago
CVRx Reports Preliminary First Quarter 2025 Financial Results
MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. “While we continue to make... Full story
Yahoo Finance • 7 months ago
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (T... Full story
Yahoo Finance • 8 months ago
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neur... Full story
Yahoo Finance • 2 years ago
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
CMS Increases Outpatient Payment for Barostim Procedure
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant proce... Full story
Yahoo Finance • 2 years ago
CVRx Reports Third Quarter 2023 Financial and Operating Results
MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
MINNEAPOLIS, Oct. 12, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neur... Full story
Yahoo Finance • 2 years ago
CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023
MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neur... Full story
Yahoo Finance • 2 years ago
CVRx Set to Join Russell 2000 & 3000 Indexes
MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 2 years ago
CVRx Reports First Quarter 2023 Financial and Operating Results
MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 3 years ago
Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure
MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neu... Full story
Yahoo Finance • 3 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NYSE: CVRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomla... Full story
